Recently, JMJD2B has been recognized as a strong epigenetic modulator of inflammation (65), and have attracted much attention in the malignant progression of multiple types of cancer, such as breast cancer, gastric cancer, colorectal cancer, bladder cancer, and lung cancer (66–72). This evidence concerns the gene KDM4B and gastric cancer.